Human Reproduction, Vol 12, 1129-1137, Copyright © 1997 by Oxford University Press
U Elchalal and JG Schenker
Ovarian hyperstimulation syndrome (OHSS) is a serious complication
affecting ovulation induction. Its most severe manifestation takes the form
of massive ovarian enlargement and multiple cysts, haemoconcentration and
third-space accumulation of fluid. The full- blown clinical syndrome may be
complicated by renal failure and oliguria, hypovolaemic shock,
thromboembolic episodes, adult respiratory distress syndrome (ARDS), and
death. Although the pathophysiology of this syndrome has not been
completely elucidated, it seems likely that the increased capillary
permeability triggered by the release of vasoactive substance secreted by
the ovaries under human chorionic gonadotrophin (HCG) stimulation plays a
key role in this syndrome. Several factors such as histamine, serotonin,
prostaglandins, prolactin, and a variety of other substances have been
implicated in this process in the past. At present, factors belonging to
the renin- angiotensin system, cytokines including the interleukins, tumour
necrosis factor alpha, endothelin-1 and vascular endothelial growth factor
(VEGF) are thought to be involved in triggering increased vascular
permeability after ovulation induction treatment. This manuscript
summarizes the current knowledge of the pathophysiology of ovarian
hyperstimulation syndrome with emphasis on the correlation of the various
factors with the clinical phenomena of this iatrogenic syndrome.
REVIEWS
The pathophysiology of ovarian hyperstimulation syndrome--views and ideas
Department of Obstetrics and Gynecology, Hadassah Medical Center, The Hebrew University, Jerusalem, Israel.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
D M Raw and M C Collins Internal jugular vein thrombosis and ovarian hyperstimulation syndrome J R Soc Med, July 1, 2007; 100(7): 339 - 340. [Full Text] [PDF] |
||||
![]() |
K. Kosaka, H. Fujiwara, S. Yoshioka, and S. Fujii Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome Hum. Reprod., June 1, 2007; 22(6): 1647 - 1651. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. De, J.-I. Park, K. Kawamura, R. Chen, C. Klein, R. Rauch, S. M. Mulders, M. D. Sollewijn Gelpke, and A. J. W. Hsueh Intraovarian Tumor Necrosis Factor-Related Weak Inducer of Apoptosis/Fibroblast Growth Factor-Inducible-14 Ligand-Receptor System Limits Ovarian Preovulatory Follicles from Excessive Luteinization Mol. Endocrinol., October 1, 2006; 20(10): 2528 - 2538. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Wiser, J. Levron, D. Kreizer, R. Achiron, A. Shrim, E. Schiff, J. Dor, and A. Shulman Outcome of pregnancies complicated by severe ovarian hyperstimulation syndrome (OHSS): a follow-up beyond the second trimester Hum. Reprod., April 1, 2005; 20(4): 910 - 914. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Delbaere, G. Smits, O. Olatunbosun, R. Pierson, G. Vassart, and S. Costagliola New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome? Hum. Reprod., March 1, 2004; 19(3): 486 - 489. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Vasseur, P. Rodien, I. Beau, A. Desroches, C. Gerard, L. de Poncheville, S. Chaplot, F. Savagner, A. Croue, E. Mathieu, et al. A Chorionic Gonadotropin-Sensitive Mutation in the Follicle-Stimulating Hormone Receptor as a Cause of Familial Gestational Spontaneous Ovarian Hyperstimulation Syndrome N. Engl. J. Med., August 21, 2003; 349(8): 753 - 759. [Full Text] [PDF] |
||||
![]() |
G. Smits, O. Olatunbosun, A. Delbaere, R. Pierson, G. Vassart, and S. Costagliola Ovarian Hyperstimulation Syndrome Due to a Mutation in the Follicle-Stimulating Hormone Receptor N. Engl. J. Med., August 21, 2003; 349(8): 760 - 766. [Full Text] [PDF] |
||||
![]() |
Z.O. Amarin Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome: An aggressive, but perhaps life-saving procedure Hum. Reprod., April 1, 2003; 18(4): 659 - 664. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Endo, H. Honnma, T. Hayashi, M. Chida, K. Yamazaki, Y. Kitajima, A. Azumaguchi, H. Kamiya, and R. Kudo Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos Hum. Reprod., October 1, 2002; 17(10): 2548 - 2551. [Abstract] [Full Text] [PDF] |
||||



